SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059555
Filing Date
2024-05-14
Accepted
2024-05-14 16:12:35
Documents
88
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tsha-20240331.htm   iXBRL 10-Q 1613298
2 EX-31.1 tsha-ex31_1.htm EX-31.1 15711
3 EX-31.2 tsha-ex31_2.htm EX-31.2 15747
4 EX-32.1 tsha-ex32_1.htm EX-32.1 8926
5 EX-32.2 tsha-ex32_2.htm EX-32.2 8962
6 GRAPHIC img39569174_0.jpg GRAPHIC 15187
7 GRAPHIC img39569174_1.jpg GRAPHIC 76090
8 GRAPHIC img39569174_2.jpg GRAPHIC 28410
9 GRAPHIC img39569174_3.jpg GRAPHIC 29775
10 GRAPHIC img39569174_4.jpg GRAPHIC 82564
11 GRAPHIC img39569174_5.jpg GRAPHIC 27437
12 GRAPHIC img39569174_6.jpg GRAPHIC 24306
13 GRAPHIC img39569174_7.jpg GRAPHIC 54319
  Complete submission text file 0000950170-24-059555.txt   9483239

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tsha-20240331.xsd EX-101.SCH 1544151
91 EXTRACTED XBRL INSTANCE DOCUMENT tsha-20240331_htm.xml XML 1478120
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39536 | Film No.: 24944479
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)